CLOs on the Move

Beigene

www.beigene.com

 
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.beigene.com
  • 55 Cambridge Parkway Suite 700W
    Cambridge, CA USA 02142
  • Phone: 781.801.1800

Executives

Name Title Contact Details
Sanjeeve Bala
 Vice President, US Regulatory Affairs Profile
Mark Dizon
 Assistant General Counsel, Chief Compliance Officer Profile
Mark Dizon
 Assistant General Counsel and Chief Compliance Officer Profile
Jamie Gillette
 Senior Director, Regulatory Affairs Profile
Sophia Ng
 Sr. Director and Sr. Corporate Counsel Profile

Similar Companies

Fremont Analytical Inc

Fremont Analytical Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Promosome

Promosome is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

One Cell Systems

One Cell Systems is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.